Annotation Detail
Information
- Associated Genes
- NTRK3
- Associated Variants
- NTRK3 ETV6-NTRK3
- Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatment with larotrectinib resulted in reduced tumour burden for all patients with NTRK fusions. The average time on treatment was 28.4 months for patients with NTRK fusion cancer, compared to 1.8 months for those without an NTRK fusion.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7496
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3985
- Variant URL
- https://civic.genome.wustl.edu/links/variants/801
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Larotrectinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 30624546
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Larotrectinib | Sensitivity | true |